argenx SE - American Depositary Shares (ARGX)
Frequently Asked Questions About argenx SE - American Depositary Shares (ARGX)
Has argenx SE received any regulatory approvals?
Yes, argenx SE has received regulatory approvals for its lead product, efgartigimod. The U.S. FDA granted Breakthrough Therapy Designation for the treatment of myasthenia gravis, and the European Medicines Agency (EMA) has also recognized its potential in treating autoimmune diseases. These designations facilitate expedited development and review, underscoring the promising nature of the therapy.
How can investors keep updated on argenx SE's progress?
Investors can stay updated on argenx SE's progress by regularly checking the company’s official website, attending earnings calls, reviewing press releases regarding clinical trials and partnerships, and following the company on financial news platforms and social media. This allows stakeholders to access the latest information regarding the company’s development activities and financial performance.
How does argenx engage with the patient community?
argenx SE is committed to engaging with the patient community as part of its mission to better understand the needs of those affected by the diseases it aims to treat. This includes collaborating with patient advocacy groups, conducting surveys, hosting educational events, and actively soliciting patient feedback during clinical trials to ensure that its therapies are designed with the patient's perspective in mind.
How does argenx SE ensure the safety and efficacy of its products?
argenx SE ensures the safety and efficacy of its products through rigorous clinical trials that adhere to international regulatory standards. Detailed preclinical evaluations and phased clinical trials assess the therapeutic candidates’ safety profile and effectiveness before they are submitted for regulatory approval, ensuring a comprehensive understanding of their potential impact on patients.
Is argenx SE publicly traded?
Yes, argenx SE is publicly traded. Its American Depositary Shares (ADS) are listed on the Nasdaq Stock Market under the ticker symbol 'ARGX'. The company went public in 2017 and has since gained visibility in the biopharmaceutical sector, attracting investment to fund its research and development efforts.
What are some of argenx SE's key product candidates?
Among argenx SE's key product candidates are efgartigimod (ARGX-113), which is in development for autoimmune diseases, and cusatuzumab (ARGX-110), aimed at treating cancer. Efgartigimod has shown promise in clinical trials for conditions such as myasthenia gravis, while cusatuzumab targets CD70 to potentially treat acute myeloid leukemia (AML).
What are the clinical indications for argenx's therapies?
argenx SE is primarily focused on developing therapies for autoimmune diseases and certain cancers. Specific clinical indications under investigation include myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), pemphigus vulgaris, and acute myeloid leukemia (AML). The company's innovative approach aims to address significant unmet medical needs in these areas.
What are the future goals for argenx SE?
The future goals for argenx SE involve advancing its promising pipeline of therapeutic candidates through clinical development, achieving regulatory approvals, and ultimately bringing effective therapies to market. The company aims to expand its global footprint, foster innovation in biologics, and continuously address unmet medical needs in autoimmune diseases and cancer, driving growth and benefiting patients worldwide.
What collaborations or partnerships does argenx have?
argonx SE engages in various collaborations and partnerships to enhance its research capabilities and expedite the development of its product pipeline. These alliances may involve academic institutions, biotech companies, and pharmaceutical firms, enabling shared expertise and funding to advance innovative therapies and explore new therapeutic areas.
What does argenx SE do?
argenx SE is a biopharmaceutical company focused on developing innovative antibody therapies for the treatment of severe autoimmune diseases and cancer. The company uses its proprietary SIMPLE Antibody™ platform to create novel therapeutics that can target specific disease mechanisms, with the aim of providing effective treatments that address unmet medical needs.
What is efgartigimod?
Efgartigimod (ARGX-113) is an experimental therapeutic designed to reduce pathogenic IgG antibodies in patients with autoimmune diseases. It works by targeting the neonatal Fc receptor (FcRn), leading to a decrease in the circulating levels of these antibodies, which play a significant role in various autoimmune disorders. Efgartigimod has shown encouraging results in clinical trials for diseases like myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP).
What is the company's approach to drug development?
argenx SE adopts a patient-centered approach to drug development, focusing on understanding and addressing the specific biological mechanisms underlying autoimmune diseases and cancer. By leveraging their SIMPLE Antibody™ platform, the company aims to design targeted therapies that can offer effective and safe treatment options, resulting in substantial improvements in patient outcomes.
What is the company's mission?
The mission of argenx SE is to transform the treatment landscape for patients suffering from autoimmune diseases and cancer by developing innovative therapies that are based on their proprietary technology. The company is dedicated to making a significant impact on patient lives by addressing the underlying causes of disease through targeted therapeutics.
What is the company's research and development strategy?
argenx SE's research and development strategy focuses on leveraging its SIMPLE Antibody™ platform to create targeted therapies for unmet medical needs in autoimmune diseases and cancer. The company prioritizes advancements in preclinical and clinical development, with a strong emphasis on collaboration and partnerships to enhance its scientific research and expedite the development process.
What is the company’s financial outlook?
While specific future financial performance can vary based on market conditions and clinical development outcomes, argenx SE has bolstered its financial position through successful capital raises since its IPO. With a strong pipeline of product candidates and potential partnerships, the company hopes to maintain growth and expand its market presence while pursuing long-term profitability.
What is the significance of the American Depositary Shares (ADS)?
American Depositary Shares (ADS) represent shares of a foreign company that are traded on U.S. stock exchanges. For argenx SE, the ADS allows U.S. investors to participate in the company’s growth and success without needing to deal directly with foreign stock markets. ADS provides a means to invest in argenx's promising biopharmaceutical innovations while benefiting from the liquidity and accessibility of the U.S. markets.
What is the SIMPLE Antibody™ platform?
The SIMPLE Antibody™ platform is an innovative technology developed by argenx SE that allows for the creation of highly specialized antibodies. This platform is designed to streamline the process of antibody discovery, enabling the company to develop therapeutic candidates that can effectively bind to and modulate disease targets with high precision, thereby enhancing efficacy and safety.
Where is argenx SE headquartered?
argenx SE is headquartered in Zug, Switzerland, which serves as a central hub for the company's operations, research, and development activities. Additionally, the company has a strong presence in the United States, where it has built a team to advance its product candidates through clinical development and commercialization.
Who are the key members of argenx's leadership team?
The leadership team at argenx includes experienced professionals from various sectors in biotechnology and pharmaceuticals. CEO and co-founder Tim Van Hauwermeiren, along with other executives, bring extensive expertise in drug development, regulatory affairs, and commercial strategy, positioning the company strategically within the biopharmaceutical landscape.
What is the current price of argenx SE - American Depositary Shares?
The current price of argenx SE - American Depositary Shares is 591.14
When was argenx SE - American Depositary Shares last traded?
The last trade of argenx SE - American Depositary Shares was at 10:34 am EDT on April 3rd, 2025